Edition:
United States

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

14.27USD
27 Mar 2017
Change (% chg)

$0.51 (+3.71%)
Prev Close
$13.76
Open
$13.59
Day's High
$14.32
Day's Low
$13.59
Volume
105,763
Avg. Vol
157,994
52-wk High
$21.75
52-wk Low
$11.37

Latest Key Developments (Source: Significant Developments)

Amphastar Pharma Q4 gaap loss per share $0.06
Monday, 13 Mar 2017 04:21pm EDT 

Amphastar Pharmaceuticals Inc : Amphastar Pharmaceuticals reports financial results for the three months and fiscal year ended December 31, 2016 . Q4 gaap loss per share $0.06 . Q4 revenue $63.5 million versus I/B/E/S view $55.8 million . Q4 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S .Q4 adjusted non-GAAP earnings per share $0.01.  Full Article

Momenta Pharmaceuticals says U.S. Court of Appeals reversed district court's dismissal filed by Amphastar Pharma against Co
Wednesday, 8 Mar 2017 09:01am EST 

Amphastar Pharmaceuticals Inc : Momenta Pharmaceuticals- on March 6, U.S. Court of Appeals for first circuit reversed district court's dismissal filed by Amphastar Pharma against Co .Momenta Pharmaceuticals- suit by Amphastar against Co alleged Momenta, Sandoz sought to prevent Amphastar from selling generic enoxaparin sodium injection.  Full Article

Amphastar announces the receipt of a CRL for Intranasal Naloxone for the emergency treatment of opioid overdose
Tuesday, 21 Feb 2017 06:00am EST 

Amphastar Pharmaceuticals Inc : Amphastar announces the receipt of a CRL for Intranasal Naloxone for the emergency treatment of opioid overdose . Amphastar Pharmaceuticals Inc - CRL identifies issues including user human factors study, device evaluation, and other items that need to be addressed .Amphastar Pharmaceuticals Inc - Will continue to offer Naloxone in pre-filled syringes while we pursue NDA for Intranasal Naloxone.  Full Article

Amphastar Pharmaceuticals receives Complete Response Letter
Tuesday, 27 Dec 2016 06:00am EST 

Amphastar Pharmaceuticals Inc : Amphastar Pharmaceuticals Inc - CRL indicated that armstrong should make further changes to label and packaging for Primatene Mist . Amphastar Pharma - intend to continue to work with fda to address their concerns in CRL by middle of 2017 and bring Primatene Mist back to OTC market . Amphastar Pharmaceuticals receives complete response letter for Primatene® Mist . Amphastar Pharmaceuticals Inc - Amphastar is evaluating content of letter and plans further discussions with FDA .Amphastar Pharma - CRL indicated that armstrong should conduct another human factor validation study.  Full Article

Amphastar Pharma Q2 adjusted non-gaap earnings per share $0.23
Monday, 8 Aug 2016 04:05pm EDT 

Amphastar Pharmaceuticals Inc : Q2 gaap earnings per share $0.15 . Q2 earnings per share view $0.01 -- Thomson Reuters I/B/E/S . Amphastar pharmaceuticals reports financial results for the three months ended june 30, 2016 . Q2 revenue $68 million versus i/b/e/s view $62.1 million .Q2 adjusted non-gaap earnings per share $0.23.  Full Article

Amphastar buys International Medication Systems(UK)for $7.7 mln
Thursday, 4 Aug 2016 06:00am EDT 

Amphastar Pharmaceuticals Inc : Purchases International Medication Systems (UK) Limited from UCB Pharma GMBH .Deal for $7.7 million.  Full Article

Amphastar Pharmaceuticals Q1 EPS $0.05
Monday, 9 May 2016 04:05pm EDT 

Amphastar Pharmaceuticals Inc : Amphastar pharmaceuticals reports financial results for the first quarter ended march 31, 2016 . Q1 earnings per share $0.05 . Q1 revenue $59.4 million versus i/b/e/s view $62 million . Q1 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S .Q1 adjusted non-gaap earnings per share $0.12.  Full Article

Amphastar Pharmaceuticals Inc Receives Approval for AMPHADASE Supplement
Monday, 22 Jun 2015 06:00am EDT 

Amphastar Pharmaceuticals Inc:Says the U.S. Food and Drug Administration (FDA) granted approval of the company's New Drug Application (NDA) supplement for Amphadase (hyaluronidase injection).Says this marks the first FDA approved starting material from the company's subsidiary, ANP, located in Nanjing, China, and signifies that this facility has been qualified by the FDA.  Full Article

More From Around the Web

BRIEF-Amphastar Pharma Q4 gaap loss per share $0.06

* Amphastar Pharmaceuticals reports financial results for the three months and fiscal year ended December 31, 2016